Table 3.
Results of muscle activation (µV) during maximum voluntary isometric contraction.
| EI group | CI group | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| T1 (16) | T2 (16) | T3 (15) | T4 (11) | T1 (13) | T2 (13) | T3 (9) | T4 (5) | ||
| Dorsal flexion | Tibialis anterior (ag) | 73.15 (58.44) | 109.17 (161.06)* | 97.88 (137.51) | 110.20 (143.97) | 56.38 (56.20) | 84.85 (64.37) | 69.10 (2.10) | 75.39 (64.69) |
| Strength gain (%) | 49.24% | ||||||||
| Gastrocnemius (atg) | 33.86 (51.67) | 19.58 (30.40)* | 17.66 (25.79)* | 22.74 (30.76) | 13.57 (9.29) | 14.35 (9.87) | 18.50 (13.69) | 21.54 (12.85) | |
| Strength gain (%) | − 42.17 | − 47.84% | |||||||
| Knee extension | Rectus femoris (ag) | 108.57 (100.76) | 139.42 (94.03)* | 128.27 (110.00) | 75.83 (61.13) | 57.76 (6.19) | 81.51 (49.72) | 72.88 (28.66) | 73.80 (31.95) |
| Strength gain (%) | 28.41% | ||||||||
| Biceps femoris | 23.22 (19.68) | 21.80 (14.46) | 26.06 (26.46) | 24.65 (21.70) | 16.79 (9.47) | 22.83 (17.47) | 21.17 (21.98) | 20.39 (18.46) | |
| Hip abduction | Gluteus maximum (ag) | 52.46 (59.30) | 73.46 (68.35)* | 67.89 (77.29) | 57.82 (65.37) | 47.15 (69.37) | 69.31 (85.02)* | 40.55 (53.04) | 24.12 (21.00) |
| Strength gain (%) | 40.03% | 47.00% | |||||||
| Hip extension | Biceps femoris (ag) | 79.68 (82.88) | 99.92 (112.06)* | 105.48 (123.85) | 99.90 (138.02) | 65.54 (45.52) | 94.36 (59.06)* | 82.65 (61.20) | 81.63 (62.88) |
| Strength gain (%) | 25.40% | 57.70% | |||||||
| Rectus femoris (atg) | 39.20 (49.90) | 24.42 (28.21)* | 22.81 (4.71) | 30.25 (34.81) | 42.35 (45.58) | 39.28 (39.50) | 36.30 (30.13) | 13.12 (10.78) | |
| Strength gain (%) | − 37.70% | ||||||||
| Plantar flexion | Gastrocnemius (ag) | 34.89 (36.87) | 51.79 (78.48) | 39.65 (52.55) | 31.87 (48.87) | 28.71 (17.05) | 35.35 (34.84) | 30.01 (23.97) | 51.47 (38.89) |
| Tibialis anterior (atg) | 23.16 (19.75) | 18.45 (18.16) | 16.95 (18.07) | 21.45 (21.81) | 37.21 (33.50) | 37.35 (32.01) | 44.76 (58.58) | 58.59 (43.35) | |
T1 pre-intervention assessment, T2 post-intervention assessment, T3 one month follow-up, T4 three months follow-up, Ag agonist, Atg antagonist.
*p < 0.05 with T1. Results are expressed as mean (SD).